sponsored
PatientsVille.com Logo

PatientsVille

Umbilical Medical Research Studies

Up-to-date List of Umbilical Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Umbilical Medical Research Studies

Rank Status Study
1 Unknown  Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients
Conditions: Liver Cirrhosis;   Radiology;   Mesenchymal Stem Cells;   Umbilical Cord
Interventions: Biological: Umbilical cord Mesenchymal Stem Cells;   Drug: Conserved therapy
Outcome Measures: The result of liver function and liver histological improvement.;   The disappearance or reduction of abdominal dropsy;   The clinical symptom improve(including food appetite,debilitation,abdominal distension,edema of lower limbs )
2 Unknown  Laparoscopic or Conventional Mesh Repair of Incisional and Umbilical Hernia
Conditions: Incisional Hernia;   Umbilical Hernia
Interventions: Procedure: Laparoscopic mesh hernia repair;   Procedure: Open anterior approach
Outcome Measures: Parietal postoperative complications: 1- haematoma, 2- abscess, 3- seroma 4- cutaneous necrosis;   Postoperative intra abdominal complications: peritonitis, occlusion, haemorrhage;   Postoperative pain: measured by a- Visual Analogic Score (VAS 0-10): 1-number of days with VAS > 5; 2- maximal VAS, and b- duration (days) of morphine use;   Postoperative fever > 38°5;   Postoperative ileus;   Postoperative phlebitis;   Postoperative pulmonary embolism;   Postoperative urinary infection;   Duration of hospital stay;   Duration of drainage;   Mesh infection;   Peritonitis due to intraperitoneal mesh;   Occlusion due to intra peritoneal mesh;   Recurrence of incisional or Umbilical hernia;   Trocar site hernia
3 Unknown  Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot
Conditions: Diabetic Foot;   Critical Limb Ischemia;   Mesenchymal Stem Cells;   Umbilical Cord
Interventions: Biological: Umbilical cord mesenchymal stem cells;   Drug: Standard Therapy
Outcome Measures: Angiographic evaluation of angiogenesis at ischemic limb;   Pain;   Ankle-Brachial pressure index;   Wound healing (wound size, wound stage);   Walking distance;   Rate and extent of amputations
4 Recruiting The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants
Condition: Intraventricular Hemorrhage
Interventions: Procedure: Umbilical Cord Milking;   Procedure: Delayed Cord Clamping
Outcome Measures: Superior Vena Cava Flow;   Delivery Room Interventions;   Hemoglobin;   Neurodevelopmental impairment 18-36 months;   Severe intraventricular hemorrhage (grade 3 or 4);   Phototherapy;   Ionotropic support;   Neonatal intensive care unit (NICU) length of stay;   Necrotizing enterocolitis;   Number of blood transfusions while in the neonatal intensive care unit;   Ventilator time;   Apgar score <7 at 5 minutes;   Umbilical cord pH < 7.0;   Blood pressure in first 2 hours of admission to neonatal intensive care unit;   Polycythemia;   Neonatal death;   Use of uterotonic agents;   Peak transcutaneous and/or serum bilirubin concentrations;   Maternal hemoglobin;   Intraventricular Hemorrhage detected on Head Ultrasound
5 Recruiting Umbilical Cord Blood Therapy for Global Developmental Delay
Condition: Global Developmental Delay
Intervention: Procedure: Umbilical Cord Blood administration
Outcome Measures: Changes in Cognition;   Changes in Cognitive Neurodevelopmental Outcome;   Changes in Motor Performance;   Changes in Standardized Gross Motor Function;   Changes in Motor Neurodevelopmental Outcome;   Changes in Functional Independence in Daily Activities;   Changes in Visual Perception Test;   Changes in Muscle Strength;   Changes in Functional Performance in Daily Activities;   Changes in Language Evaluation;   Changes in Brain glucose metabolism
6 Recruiting Milking the Umbilical Cord for Extreme Preterm Infants
Condition: Infant, Premature
Intervention: Procedure: Milking the Umbilical cord before cord clamping
Outcome Measures: To evaluate and compare hemoglobin and hematocrit concentrations in extremely low birth weight infants (ELVW) after cord milking intervention to ELBW infants receiving immediate cord clamping;   To evaluate and compare the incidence and numbers of blood transfusions after cord milking;   To evaluate and compare blood pressure after intervention and need for support medications;   To evaluate and compare the incidence of hyperbilirubinemia and length of phototherapy;   To evaluate the incidence of complications of prematurity in the study and control groups;   To evaluate long term outcomes of prematurity in both groups in a follow-up study;   To compare the difference in hemoglobin and hematocrit from Umbilical cord blood
7 Recruiting Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients With Ascites and Liver Cirrhosis
Conditions: Umbilical Hernia;   Liver Cirrhosis;   Ascites
Interventions: Procedure: Conservative treatment;   Procedure: Surgical repair
Outcome Measures: complications;   Recurrence;   Mortality;   Length of hospital stay;   Quality of life;   Cost effectiveness
8 Unknown  Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
Conditions: Hematological Malignancy;   Bone Marrow Failure Syndrome
Interventions: Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders;   Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders;   Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Outcome Measures: To determine the safety and efficacy of multiple cord blood transplantation in patients with hematological malignancy.;   To determine the 100-day treatment related mortality (TRM), complete remission rate and the 2-year progression free and overall survival rate for patients under going this treatment.;   To determine the incidence of grades II-IV and grades III-IV acute GVHD and incidence of limited and extensive chronic GVHD.;   To measure time to immunologic reconstitution as defined by normal numbers of T and B-cells and normal immunoglobulin synthesis;   To determine rate of hematologic engraftment following Umbilical cord blood transplantation with 1-2 cord blood units using total body irradiation & fludarabine as transplant conditioning regimen & cyclosporine/MMF as graft-vs-host disease prophylaxis
9 Recruiting A Research Study Looking at Specific Tissue of the Umbilical Cord
Condition: Varices of Umbilical Cord
Intervention:
Outcome Measures: Isolation and decellularization of Umbilical cord Wharton's jelly matrix;   Study the ability of the isolated and decellularized matrix to support recellularization with mesenchymal stem cells and to support their growth and differentiation
10 Recruiting Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit ATG;   Procedure: Double Umbilical Cord Blood Transplantation;   Procedure: Haplo-Identical Cord Transplantation
Outcome Measures: Rate of neutrophil engraftment after combined haplo-identical cord with that of Umbilical cord blood transplantation.;   Platelet recovery after transplant regimens;   Transfusion requirements after haplo-identical Umbilical cord blood transplant versus double Umbilical cord blood transplant;   Transplant-related mortality (TRM), relapse rate, survival and progression free survival;   Incidence of acute and chronic GVHD;   Severity of opportunistic infections
11 Recruiting Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: Umbilical cord blood transplantation;   Radiation: total-body irradiation;   Other: laboratory biomarker analysis
Outcome Measures: Overall survival;   Incidence of non-relapse mortality;   Incidence of graft failure/rejection;   Incidence of neutrophil engraftment;   Incidence of platelet engraftment;   Incidence of grade II-IV and III-IV acute GVHD for each arm;   Incidence of chronic GVHD for each arm;   Incidence of relapse or disease progression;   Progression-free survival;   Incidence of clinically significant infections
12 Recruiting Umbilical Cord Care for the Prevention of Colonization
Conditions: Line Insertion Site;   Central Line-associated Bloodstream Infection (CLABSI)
Interventions: Drug: Povidone-Iodine;   Drug: Chlorhexidine gluconate;   Drug: Pluronic Cream;   Other: control
Outcome Measures: Colonization of Umbilical stump;   Late-onset infection;   Contact dermatitis of cord or skin base
13 Unknown  Immediate VS Delayed Cord Clamping on Newborns
Conditions: Newborn;   Umbilical Cord
Intervention: Procedure: different time of Umbilical cord clamping
Outcome Measures: hemoglobin level of the baby 1 month after birth;   departure time of the Umbilical cord
14 Recruiting Intrabone Infusion of Umbilical Cord Blood Stem Cells
Condition: Hematopoietic Stem Cell Transplantation
Intervention: Procedure: Intrabone infusion of Umbilical cord blood stem cells
Outcome Measures: Platelet recovery rate;   Neutrophil recovery rate;   Immunological reconstitution;   Donor chimerism rate;   Acute GVHD (grade 2-4) rate;   Infection rate (bacterial, viral, fungal and parasitic);   Event-free and overall survival;   Adverse infections (grade and frequency);   chronic GVHD
15 Recruiting Comparative Study Matching Intraperitoneal Onlay Mesh (IPOM) and Sublay Mesh to Treat Umbilical Hernia
Condition: Umbilical Hernia
Interventions: Procedure: intraperitoneal onlay mesh repair;   Procedure: sublay mesh repair
Outcome Measures: early wound complications;   late wound complications;   complication rate perioperative;   duration of operation;   hospital stay;   Umbilical hernia recurrence rate;   navel site seroma;   complication rate postoperative;   pain score (Visual Analog Scale - VAS);   Quality of life (SF-36)
16 Recruiting Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome
Condition: Hypoplastic Left Heart Syndrome
Intervention: Biological: autologous cell-based delivery
Outcome Measures: Number of patients completing consent, collection of Umbilical cord blood, and intramyocardial delivery of autologous stem cells;   Number of patients with cardiac-related adverse events;   Change in right ventricular ejection fraction according to cardiac imaging with echocardiography
17 Recruiting Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
Condition: Autism Spectrum Disorder
Intervention: Biological: Autologous Umbilical Cord Blood
Outcome Measures: Number of participants with non-serious and serious adverse events.;   The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II
18 Recruiting The Effect of Cord Milking on Hemodynamic Status of Preterm Infants
Condition: Preterm Infants
Interventions: Procedure: Milking the Umbilical cord at birth;   Procedure: immediate Umbilical cord clamping
Outcome Measures: Systemic blood flow as reflected by mean SVC flow measured by echocardiographic study at 4-6 hours after birth.;   low SVC flow (< 40 ml/kg/min), as assessed by echocardiography;   Hypotension;   Hyperbilirubinemia and peak bilirubin level recording;   Systemic blood flow as reflected by mean SVC flow measured by echocardiographic study at 10-12 hours after birth.;   Number of blood transfusions during hospital stay;   Intraventricular hemorrhage (IVH);   Neurodevelopmental outcome
19 Recruiting T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: Umbilical cord blood transplantation;   Drug: Allopurinol;   Drug: fludarabine phosphate;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Treg infusion;   Drug: Sirolimus
Outcome Measures: Maximum tolerated dose;   Number of patients with detectable Treg cells;   Number of Patients with grade II-IV and grade III-IV acute graft versus host disease (GVHD);   Number of patients with sustained donor engraftment;   Number of patients with double chimerism;   Incidence of neutrophil recovery after Umbilical cord blood (UCB) transplantation;   Number of Patients with Chronic Graft Versus Host Disease (GVHD);   Number of Patients with disease-free survival;   Number of Patients with Fungal and Viral Infections;   Incidence of platelet recovery after Umbilical cord blood (UCB);   Number of Patients with Disease Relapse;   Percent of Patients with Immune Cell Recovery
20 Unknown  Delayed Umbilical Cord Clamping in Infants Less Than 32 Weeks
Condition: Premature Birth
Intervention: Procedure: Umbilical cord clamping
Outcome Measures: Primary Composite outcome of Intraventricular Hemorrhage and/or Late Onset Sepsis;   Secondary outcomes include: 1) lung function 2) cardiovascular function and 3) anemia.

These studies may lead to new treatments and are adding insight into Umbilical etiology and treatment.

A major focus of Umbilical research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Umbilical